WallStreetZenWallStreetZen

NASDAQ: ENLV
Enlivex Therapeutics Ltd Stock Forecast, Predictions & Price Target

Analyst price target for ENLV

Based on 2 analysts offering 12 month price targets for Enlivex Therapeutics Ltd.
Min Forecast
$6.00+279.75%
Avg Forecast
$9.50+501.27%
Max Forecast
$13.00+722.78%

Should I buy or sell ENLV stock?

Based on 2 analysts offering ratings for Enlivex Therapeutics Ltd.
Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their ENLV stock forecasts and price targets.

ENLV stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-09-27
lockedlocked$00.00+00.00%2024-09-26

1 of 1

Forecast return on equity

Is ENLV forecast to generate an efficient return?
Company
N/A
Industry
-264.3%
Market
52.28%

Forecast return on assets

Is ENLV forecast to generate an efficient return on assets?
Company
N/A
Industry
21.36%

ENLV earnings per share forecast

What is ENLV's earnings per share in the next 2 years based on estimates from 1 analyst?
Avg 1 year Forecast
-$0.70
Avg 2 year Forecast
-$0.58

ENLV vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ENLV$1.58$9.50+501.27%Strong Buy
PMN$1.11N/AN/A
MLEC$0.89N/AN/A
QNCX$0.75N/AN/A
SRZN$10.50N/AN/A

Enlivex Therapeutics Stock Forecast FAQ

Is Enlivex Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: ENLV) stock is to Strong Buy ENLV stock.

Out of 2 analysts, 1 (50%) are recommending ENLV as a Strong Buy, 1 (50%) are recommending ENLV as a Buy, 0 (0%) are recommending ENLV as a Hold, 0 (0%) are recommending ENLV as a Sell, and 0 (0%) are recommending ENLV as a Strong Sell.

If you're new to stock investing, here's how to buy Enlivex Therapeutics stock.

What is ENLV's earnings growth forecast for 2024-2025?

(NASDAQ: ENLV) Enlivex Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.45%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.47%.

Enlivex Therapeutics's earnings in 2024 is -$22,294,000.On average, 1 Wall Street analyst forecast ENLV's earnings for 2024 to be -$14,618,318, with the lowest ENLV earnings forecast at -$14,618,318, and the highest ENLV earnings forecast at -$14,618,318.

In 2025, ENLV is forecast to generate -$12,112,321 in earnings, with the lowest earnings forecast at -$12,112,321 and the highest earnings forecast at -$12,112,321.

What is ENLV's forecast return on equity (ROE) for 2024-2026?

(NASDAQ: ENLV) forecast ROE is N/A, which is considered weak.

What is ENLV's Price Target?

According to 2 Wall Street analysts that have issued a 1 year ENLV price target, the average ENLV price target is $9.50, with the highest ENLV stock price forecast at $13.00 and the lowest ENLV stock price forecast at $6.00.

On average, Wall Street analysts predict that Enlivex Therapeutics's share price could reach $9.50 by Sep 27, 2025. The average Enlivex Therapeutics stock price prediction forecasts a potential upside of 501.27% from the current ENLV share price of $1.58.

What is ENLV's Earnings Per Share (EPS) forecast for 2024-2025?

(NASDAQ: ENLV) Enlivex Therapeutics's current Earnings Per Share (EPS) is -$1.18. On average, analysts forecast that ENLV's EPS will be -$0.70 for 2024, with the lowest EPS forecast at -$0.70, and the highest EPS forecast at -$0.70. In 2025, ENLV's EPS is forecast to hit -$0.58 (min: -$0.58, max: -$0.58).

What is ENLV's forecast return on assets (ROA) for 2024-2026?

(NASDAQ: ENLV) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 21.36%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.